ArticleGene therapy2006
Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.
Article in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 65 citations in OpenAlex.
- The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.Annual review of physiology · 2017Review
- The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation.Molecular imaging and radionuclide therapy · 2017Article
- The use of the NIS reporter gene for optimizing oncolytic virotherapy.Expert opinion on biological therapy · 2016Review
- Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice.PloS one · 2015Article
- Experimental study of nasopharyngeal carcinoma radionuclide imaging and therapy using transferred human sodium/iodide symporter gene.PloS one · 2015Article
- The Na+/I- symporter (NIS): mechanism and medical impact.Endocrine reviews · 2014Review
- In vitro radionuclide therapy and in vivo scintigraphic imaging of alpha-fetoprotein-producing hepatocellular carcinoma by targeted sodium iodide symporter gene expression.Nuclear medicine and molecular imaging · 2013Article
- A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.Cancer gene therapy · 2012Article
- The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies.Current gene therapy · 2012Review
- Progress in gene therapy for prostate cancer.Frontiers in oncology · 2012Article
- Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.Human gene therapy · 2011Article
- Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer.Stem cells (Dayton, Ohio) · 2011Article
- A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.Gene therapy · 2010Article
- Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS) radioiodine gene therapy using an adenoviral system in a colon cancer model.Cancer gene therapy · 2010Article
- Genetics and phenomics of hypothyroidism and goiter due to NIS mutations.Molecular and cellular endocrinology · 2010Review
- [Study on the iodine 125 uptake of H460 lung cancer cell line by co-transfection with the human sodium/iodide symporter and the human thyroperoxidase].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Article
- Prolonged cardiac allograft survival using iodine 131 after human sodium iodide symporter gene transfer in a rat model.Transplantation proceedings · 2010Article
- The biology of the sodium iodide symporter and its potential for targeted gene delivery.Current cancer drug targets · 2010Review
- Converting tumor-specific markers into reporters of oncolytic virus infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- In Vivo Cellular Imaging for Translational Medical Research.Current medical imaging reviews · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Ovarian cancer represents the fifth leading cause of cancer death among women in the United States, with >16 000 deaths expected this year. This study was carried out to investigate the potential of sodium iodide symporter (NIS)-mediated radioiodide therapy as a novel approach for ovarian cancer treatment. Radioiodide is routinely and effectively used for the treatment of benign and malignant thyroid disease as a result of native thyroidal expression of NIS, which mediates iodide uptake. In vitro gene transfer studies in ovarian cancer cells revealed a 12- and five-fold increase in iodide uptake when transduced with Ad/CMV/NIS or Ad/MUC1/NIS, respectively. Western blot/immunohistochemistry confirmed NIS protein expression. In vivo ovarian tumor xenografts were infected with the adenoviral constructs. (123)I imaging revealed a clear image of the CMV/NIS-transduced tumor, with a less intense image apparent following infection with MUC1/NIS. Therapeutic doses of (131)I following CMV/NIS infection caused a mean 53% reduction in tumor volume (P<0.0001). MUC1/NIS-transduced tumors did not regress, although at 8 weeks following therapy, tumor volume was significantly less that of control animals (166 versus 332%, respectively, P<0.05). This study represents a promising first step investigating the potential for NIS-mediated radioiodide imaging and therapy of ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.